Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
by on Wednesday, July 25th, 2012 | No Comments
Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride; Genetic: mutation analysis; Genetic: protein expression analysis; Other: immunoenzyme technique; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Completed – verified January 2009
See the article here: Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer